Market closed

Iovance Biotherapeutics/$IOVA

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Iovance Biotherapeutics

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

Ticker

$IOVA
Sector
Health Care
Trading on
NASDAQ

Industry

Biotechnology
Headquarters
San Carlos, United States

Employees

557
Website
www.iovance.com

IOVA Metrics

BasicAdvanced
$1.8B
-
-$1.48
0.53
-

$1.8B

0.53

$18.33

$5.77

6.8M

4.223

3.839

8.713

10.206

-29.15%

-56.65%

17.664

2.28

3.77

-4.29

12,751.20%

-27.65%

-10.59%

What the Analysts think about IOVA

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Iovance Biotherapeutics stock.

IOVA Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

IOVA Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

IOVA News

AllArticlesVideos
Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025

Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025

Seeking Alpha·1 day ago
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

GlobeNewsWire·4 weeks ago
Iovance Biotherapeutics Announces the Promotion of Raj Puri, M.D., Ph.D. to Chief Regulatory Officer

Iovance Biotherapeutics Announces the Promotion of Raj Puri, M.D., Ph.D. to Chief Regulatory Officer

GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $IOVA

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Iovance Biotherapeutics stock?

Iovance Biotherapeutics (IOVA) has a market cap of $1.8B as of January 15, 2025.

What is the P/E ratio for Iovance Biotherapeutics stock?

The price to earnings (P/E) ratio for Iovance Biotherapeutics (IOVA) stock is 0 as of January 15, 2025.

Does Iovance Biotherapeutics stock pay dividends?

No, Iovance Biotherapeutics (IOVA) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Iovance Biotherapeutics dividend payment date?

Iovance Biotherapeutics (IOVA) stock does not pay dividends to its shareholders.

What is the beta indicator for Iovance Biotherapeutics?

Iovance Biotherapeutics (IOVA) has a beta rating of 0.53. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.